Bayer Group to achieve the 2010 target. "Overall, 2010 for a good year for us," Chairman of the Bayer Group Management Committee Malkin ? Dykes (MarijnDekkers), Dr. Bayer Leverkusen held on Monday at a news conference, said the financial .
"We achieved sales of 351 million euros, the company has created the highest record in history." Dr. Dai Kesi said that in 2010 the company is full of unpredictable factors. Particular sub-group of the recovery of materials technology faster than expected, has been restored to almost pre-crisis levels.glue stick Exchange rate changes also had a beneficial effect. On the other hand, crop science and medicine and health sub-group's operating results are below expectations. He never has anything on the continued development of the company expressed optimism: "We are confident this year, this year already have a good start." He said, Bayer plans to invest large sums of money within the next three years to ensure future development. 2013, the company plans to invest about 150 billion euros for research and development, property, plant and equipment.
Bayer Group sales in 2010 increased by 12.6% to 35.088 billion euros ? (2009 sales of 31.168 billion euros). glue gun The currency and portfolio adjusted basis, sales increased by 8.0%. Excluding special items, earnings before interest, taxes, depreciation and amortization (EBITDA) increased by 9.7% to 7.101 billion euros (6.472 billion euros in 2009), the exchange rate effect of approximately 400 million euros have beneficial effects. Excluding exceptional profit before interest and tax shall present an increase of 18.0%, reaching 4.452 billion euros (3.772 billion euros in 2009).
Core earnings per share increased 15% to 4.19 euros.
Bayer Group in 2010 net income of 1.722 billion euros due to special charges (in 2009 was 7.66 billion euros) which has shrunk dramatically. In the data, the impairment of about 957 million euros - including a new branding strategy for the "Schering" names of the 405 million euros a result of non-cash impairment loss. Together account for 703 million euros litigation, including 526 million euros with an expected settlement procedures, and litigation involving the United States of genetically modified rice-related litigation and defense costs. Provision for 62 million euros for the reorganization of the special fees. Net of special items, earnings before interest, taxes, depreciation and amortization fell 9.2% to 2.73 billion euros (3.006 billion euros in 2009). Net income was 13.01 billion euros (1.359 billion euros in 2009), down 4.3%. In contrast, core earnings per share increased substantially by 15.1% to 4.19 euros (3.64 euros in 2009).
Total cash flow increased 2.4% to 4.771 billion euros (4.658 billion euros in 2009), the net cash flow increased 7.4% to 5.773 billion euros (5.375 billion euros in 2009). "It is gratifying that this progress is mainly due to the whole group optimization of working capital within the scope of projects and the rising trend in income due to," Chief Financial Officer Werner ? Bauman (WernerBaumann) said. Strict capital constraints to net financial debt decreased by 18.3%, reaching 7.917 billion euros (9.691 billion euros in 2009).
Fourth quarter operating very successfully.
"On the operations side, Bayer performance in the fourth quarter of 2010 and the first three quarters as good," he added. Sales increased by 14.5% (currency and portfolio adjusted 8.1%), amounting to 9.012 billion euros (for the fourth quarter of 2009, 7.872 billion euros), without special items earnings before interest, taxes, depreciation and amortization (EBITDA) growth 11.6% to 1.689 billion euros (fourth quarter of 2009 of 15.13 billion euros). "This is mainly because of strong revenue growth in materials technology and due to favorable exchange rate impact," Bowman explained. But higher than the previous year led to special fee earnings before interest, taxes, depreciation and amortization decreased by 51 million euros (3.66 fourth quarter of 2009 billion euros).